Stockreport

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Forte Biosciences, Inc.  (FBRX) 
PDF Additional data continues to support highly differentiated profile for FB102 in celiac disease DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) ( [Read more]